Introduction Worldwide, it is estimated that about 1.3 million new gynecological cancer
cases are diagnosed each year. For 2018, the predicted annual totals were cervix uteri …

Gynecological tumor treatment, including cervical cancer (CC) treatment, often leads to
iatrogenic premature menopause. This highlights the critical importance of investigating …

Introduction Vulvovaginal atrophy (VVA) is a chronic condition caused by estrogen
deficiency. It affects around 50% of postmenopausal women, reducing their general and …

To investigate the relationship between the sex steroid receptor (estrogen receptor [ER] and
progesterone receptor [PR]) status and the cell proliferation kinetics during the menstrual …

Objective Women with gynecologic malignancies will be cured or may become long-term
survivors. Management of menopausal symptoms is important in addressing their quality of …

Decision making regarding the use of menopausal hormone therapy (MHT) for the treatment
of bothersome menopausal symptoms in a cancer survivor can be complex, and includes …

Approximately 40% of women with gynecologic malignancies are pre-or perimenopausal at
the time of diagnosis [1, 2]. Combined multimodality therapy including surgery …

Background. The immunoreactivity for progesterone receptors (PR) of the majority of
endocrine cells of the human pancreas has prompted the authors to investigate if PR …

PURPOSE: As a result of treatment, many women with gynecologic malignancies will go
through menopause and display climacteric symptoms at an earlier age than occurs …

During the 19th century, studies indicated that reproductive events were involved in cervical
cancer. Human papillomavirus (HPV) infection is a prerequisite for development of cancer …